|View printer-friendly version|
Seattle Genetics Initiates Phase II Clinical Trials With SGN-15
October 31, 2000 at 12:00 AM EST
Two Trials Commencing for Patients With Breast or Colorectal Cancers
Bothell, WA – October 31, 2000 – Seattle Genetics, Inc. announced the initiation of phase II clinical testing with one of its lead monoclonal antibody drug conjugates, SGN-15.
“We are very excited to progress into phase II with this promising anticancer agent,” stated Dr. Amy Sing, Senior Director of Medical Affairs at Seattle Genetics. Two phase II efficacy studies are being conducted, one for patients with advanced breast carcinoma and a second for patients with advanced colorectal carcinoma. Both studies will be evaluating SGN-15 in combination with the chemotherapeutic drug Taxotere®, a leading cancer treatment from Aventis Pharmaceuticals.
Seattle Genetics recently completed a phase I clinical testing of the SGN-15 and Taxotere® combination in patients with breast or colorectal carcinoma. The combination regimen was safely administered to 16 patients in the phase I study that identified the best dose of SGN-15 to be used in combination with Taxotere® in phase II. Aventis Pharmaceuticals is co-funding the clinical costs of both the phase I and phase II trials and is providing the Taxotere® drug.
The phase II studies have opened at the University of Alabama, Birmingham Comprehensive Cancer Center, Birmingham, AL; Georgia Cancer Specialists in Atlanta, GA; and the Lombardi Cancer Institute at Georgetown University Medical Center in Washington, D.C.; with other sites to be added later. “We are pleased to be testing the SGN-15 and Taxotere® combination regimen at these premier cancer centers,” stated Dr. Clay B. Siegall, President and Chief Scientific Officer of Seattle Genetics. “We are also very pleased to have the support of Aventis Pharmaceuticals, one of the world's largest pharmaceutical companies.”
Seattle Genetics, Inc. is a privately held biotechnology company focused on developing novel therapeutics to enhance the survival of cancer patients. The Company's research and development initiatives use monoclonal antibody-based therapeutics encompassing four technology platforms: antibody-drug conjugates (ADC), single-chain immunotoxins (SCIT), monoclonal antibodies (mAbs), and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has two drugs currently in four clinical trials, including SGN-10, a SCIT being tested in two phase I clinical trials in carcinoma patients, two in late-stage development and several lead agents undergoing preclinical testing. One of the late-stage development drug candidates targeted to CD40 is being developed for the treatment of certain hematologic malignancies through an alliance with Genentech, Inc.